Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A10353 | Pages: 159 | Charts: 55 | Tables: 46 |
The Gulf Pain Management Drugs Market size was valued at $851.08 million in 2019, and is projected to reach $1,047.91 million by 2027, registering a CAGR of 3.2%.
Pain is an uncomfortable sensory and emotional sensation caused due to tissue injury or disease. It is caused due to injury and various diseases such as osteoarthritis, chronic arthritis, diabetic neuropathy, multiple sclerosis, stomach ulcer, fibromyalgia and cancer. It can be defined as acute pain and chronic pain depending on duration.
Get more information on this report : Request Sample Pages
This pandemic has disrupted growth in many economies across various domains. The COVID-19 outbreak is anticipated to impact the growth of the pain management drugs market in the initial phase of the forecast period. The COVID-19 pandemic has stressed healthcare systems in the Gulf countries, so that pain services in many clinics are no longer open for public services because of safety. Furthermore, the demand for pain management drugs is expected to rise during the latter half of the forecast period owing to telemedicine which has become an appropriate and effective way to offer necessary medical services to patients with chronic pain. Through telemedicine, physicians are able to provide guidance to patients for physical exercises at-home for pain relief.
Chronic pain is mainly caused due to aging conditions of bone and joints and nerve damage and injury. Pain is managed by a particular set of drugs to reduce the symptoms or treat pain. Pain process is complex and there are various drugs that provide relief by acting through a variety of physiological mechanism. Opioids are the most prescribed pain medication. These are narcotic pain medications containing natural and synthetic opiates. Opioids are usually used for acute pain, such as short-term pain after surgery. Morphine, Fentanyl, Oxycodone and Codeine are some of the opioids used for pain management.
As per the statista, In the UAE, 4,500 new cancer cases are diagnosed each year, with cancers being the third leading cause of death after cardiovascular illnesses and injuries. This is expected to increase the need of cancer pain drugs for therapeutic purposes, thus fueling the gulf pain management drugs market growth.
In recent times there is increased use of pain management drugs due to rise in aging population. Increasing prevalence of diseases such as cancer, diabetic neuropathy, osteoarthritis and chronic arthritis, increasing number of surgical procedures and increasing healthcare expenditure are some of the key factors driving the growth for the gulf pain management drugs market. In addition, increasing healthcare awareness is also fueling the growth of gulf pain management drugs market. However, increase in generic completion, patent expiration of blockbuster drugs and availability of substitutes such as pain relief devices are some of the major factors restraining the growth for gulf pain management drugs market. In addition, prescribing drug abuse would inhibit the growth of the market.
Increasing R&D investment and outsourcing of pharmaceutical companies due to strong need for better treatment lead to market growth. In addition, novel molecule combination and drug delivery techniques would develop opportunity for the gulf pain management drugs market. However, side effects of pain management drugs could lead a challenge for the pain management drugs market.
[DRUGCLASSGRAPH]
Get more information on this report : Request Sample Pages
The gulf pain management drugs market is segmented on the basis of drug class, indication, and region. On the basis of drug class, the market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and nonnarcotic analgesics. On the basis of indication, it is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, and fibromyalgia, bone fracture, muscle sprain, acute appendicitis and other indications. On the basis of pain type, it is segmented into chronic pain and acute pain. On the basis of country, it is divided into UAE, Saudi Arabia, Oman and rest of Gulf countries.
On the basis of drug class, the opioids segment was the largest contributor to the market in 2019, owing to high efficiency of opioids to relieve pain in major chronic conditions. The anti-migraine agents segment is anticipated to possess highest growth rate during the forecast period.
[INDICATIONGRAPH]
Get more information on this report : Request Sample Pages
By indication, the neuropathic pain segment accounted for a majority of the gulf pain management drugs market share in 2019, and is expected to exhibit a prominent growth rate during the forecast period. In addition, increase in presence of large patient population is the major factor that increases demand for drugs for the segment. Cancer pain segment are expected to grow at the highest rate throughout the forecast period, owing to increase in number of surgeries and rise in prevalence of chronic diseases that lead to back pain.
The key players operating in the Gulf Pain Management Drugs Market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, Purdue Pharma L.P., Pfizer, Inc., Mylan NV., Merck & Co. Inc., Johnson & Johnson, Gulf Pharmaceutical Industries (Julphar), Oman pharmaceutical products co. Llc and GlaxoSmithKline Plc.
[COUNTRYGRAPH]
Get more information on this report : Request Sample Pages
Key Benefits For Stakeholders
Key Market Segments
Key Market Players
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Top player positioning
3.4.Porter’s five force analysis
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Rise in incidences of chronic diseases
3.5.1.2.Favorable regulatory scenario
3.5.1.3.Increase in geriatric population
3.5.2.Restraints
3.5.2.1.Availability of alternative therapies
3.5.2.2.Drug exploitation
3.5.2.3.Patent expiration of prescription drugs
3.5.3.Opportunity
3.5.3.1.Advancements in drug development
3.5.4.Impact Analysis
3.6.COVID-19 impact analysis for Gulf Pain Management Drugs
CHAPTER 4:GULF PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS
4.1.Overview
4.1.1.Market size and forecast
4.2.NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast
4.3.Anesthetics
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.4.Anticonvulsants
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.5.Antimigraine drug
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast
4.6.Antidepressants
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast
4.7.Opioids
4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast
4.8.Non-narcotic analgesics
4.8.1.Key market trends, growth factors, and opportunities
4.8.2.Market size and forecast
CHAPTER 5:GULF PAIN MANAGEMENT DRUGS MARKET, BY INDICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Arthritic pain
5.2.1.Market size and forecast
5.3.Neuropathic pain
5.3.1.Market size and forecast
5.4.Cancer pain
5.4.1.Market size and forecast
5.5.Chronic back pain
5.5.1.Market size and forecast
5.6.Post-operative pain
5.6.1.Market size and forecast
5.7.Migraine
5.7.1.Market size and forecast
5.8.Fibromyalgia
5.8.1.Market size and forecast
5.9.Bone fracture
5.9.1.Market size and forecast
5.10.Muscle sprain/strain
5.10.1.Market size and forecast
5.11.Acute appendicitis
5.11.1.Market size and forecast
5.12.Others
5.12.1.Market size and forecast
CHAPTER 6:PAIN MANAGEMENT DRUGS, BY PAIN TYPE
6.1.Overview
6.1.1.Market size and forecast
6.2.Chronic pain
6.2.1.Market size and forecast
6.3.Acute pain
6.3.1.Market size and forecast
CHAPTER 7:GULF PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY
7.1.Overview
7.1.1.Market size and forecast
7.2.UAE
7.2.1.Key market trends and growth opportunities
7.2.2.Market size and forecast, by drug class
7.2.3.Market size and forecast, by indication
7.2.4.Market size and forecast, by pain type
7.3.Saudi Arabia
7.3.1.Key market trends and growth opportunities
7.3.2.Market size and forecast, by drug class
7.3.3.Market size and forecast, by indication
7.3.4.Market size and forecast, by pain type
7.4.Oman
7.4.1.Key market trends and growth opportunities
7.4.2.Market size and forecast, by drug class
7.4.3.Market size and forecast, by indication
7.4.4.Market size and forecast, by pain type
7.5.Rest of Gulf countries
7.5.1.Key market trends and growth opportunities
7.5.2.Market size and forecast, by drug class
7.5.3.Market size and forecast, by indication
7.5.4.Market size and forecast, by pain type
CHAPTER 8:COMPANY PROFILES
8.1.ABBOTT LABORATORIES
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.2.ELI LILY AND COMPANY
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments
8.3.GLAXOSMITHKLINE PLC (GSK)
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance.
8.3.6.Key strategic moves and developments
8.4.JOHNSON & JOHNSON
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.5.MERCK & CO., INC.
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments
8.6.MYLAN N.V.
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments
8.7.NOVARTIS INTERNATIONAL AG
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.PFIZER INC.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.GULF PHARMACEUTICAL INDUSTRIES (JULPHAR)
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.10.OMAN PHARMACEUTICAL PRODUCTS CO. LLC
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
LIST OF TABLES
TABLE 01.PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 02.PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 03.PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019–2027 ($MILLION)
TABLE 04.GULF PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 05.UAE GULF PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
TABLE 06.UAE GULF PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 07.UAE GULF PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
TABLE 08.SAUDI ARABIA GULF PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
TABLE 09.SAUDI ARABIA GULF PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 10.SAUDI ARABIA GULF PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
TABLE 11.OMAN GULF PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019-2027 ($MILLION)
TABLE 12.OMAN GULF PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019-2027 ($MILLION)
TABLE 13.OMAN GULF PAIN MANAGEMENT DRUGS MARKET, BY PAIN TYPE, 2019-2027 ($MILLION)
TABLE 14.GULF PAIN MANAGEMENT DRUGS MARKET FOR OTHERS, BY DRUG CLASS, 2019-2027 ($MILLION)
TABLE 15.GULF PAIN MANAGEMENT DRUGS MARKET FOR OTHERS, BY INDICATION, 2019-2027 ($MILLION)
TABLE 16.GULF PAIN MANAGEMENT DRUGS MARKET FOR OTHERS, BY PAIN TYPE, 2019-2027 ($MILLION)
TABLE 17.ABBOTT: COMPANY SNAPSHOT
TABLE 18.ABBOTT: OERATING SEGMENT
TABLE 19.ABBOTT: PRODUCT PORTFOLIO
TABLE 20.ELI LILLY: COMPANY SNAPSHOT
TABLE 21.LILLY: OPERATING SEGMENTS
TABLE 22.ELI LILLY: PRODUCT PORTFOLIO
TABLE 23.ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 24.GSK: COMPANY SNAPSHOT
TABLE 25.GSK: OPERATING SEGMENTS
TABLE 26.GSK: PRODUCT PORTFOLIO
TABLE 27.J&J: COMPANY SNAPSHOT
TABLE 28.J&J: OPERATING BUSINESS SEGMENTS
TABLE 29.J&J: PRODUCT PORTFOLIO
TABLE 30.MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 31.MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 32.MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 33.MERCK & CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 34.MYLAN: COMPANY SNAPSHOT
TABLE 35.MYLAN: OPERATING BUSINESS SEGMENTS
TABLE 36.MYLAN: PRODUCT PORTFOLIO
TABLE 37.NOVARTIS: COMPANY SNAPSHOT
TABLE 38.NOVARTIS: OPERATING SEGMENTS
TABLE 39.NOVARTIS: PRODUCT PORTFOLIO
TABLE 40.PFIZER: COMPANY SNAPSHOT
TABLE 41.PFIZER: OERATING SEGMENT
TABLE 42.PFIZER: PRODUCT PORTFOLIO
TABLE 43.JULPHAR: COMPANY SNAPSHOT
TABLE 44.JULPHAR: PRODUCT PORTFOLIO
TABLE 45.JULPHAR: COMPANY SNAPSHOT
TABLE 46.JULPHAR: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.PAIN MANAGEMENT DRUGS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, 2017–2020
FIGURE 04.TOP WINNING STRATEGIES: NATURE AND TYPE, 2017–2020
FIGURE 05.TOP WINNING STRATEGIES: BY YEAR, 2017–2020
FIGURE 06.TOP PLAYER POSTIONING, 2019
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 09.MODERATE THREAT OF SUBSTITUTES
FIGURE 10.MODEARTE THREAT OF NEW ENTRANTS
FIGURE 11.MODERATE COMPETITIVE OF RIVALRY
FIGURE 12.IMPACT ANALYSIS, GULF PAIN MANAGEMENT DRUGS MARKET
FIGURE 13.GULF PAIN MANAGEMENT DRUGS MARKET, FOR NSAIDS, 2019-2027 ($MILLION)
FIGURE 14.GULF PAIN MANAGEMENT DRUGS MARKET, FOR ANAESTHETIC, 2019-2027 ($MILLION)
FIGURE 15.GULF PAIN MANAGEMENT DRUGS MARKET, FOR ANTICONVULSANTS, 2019-2027 ($MILLION)
FIGURE 16.GULF PAIN MANAGEMENT DRUGS MARKET, FOR ANTI-MIGRAINE AGENTS, 2019-2027 ($MILLION)
FIGURE 17.GULF PAIN MANAGEMENT DRUGS MARKET, FOR ANTIDEPRESSANTS, 2019-2027 ($MILLION)
FIGURE 18.GULF PAIN MANAGEMENT DRUGS MARKET, FOR OPIOIDS, 2019-2027 ($MILLION)
FIGURE 19.GULF PAIN MANAGEMENT DRUGS MARKET, FOR NON-NARCOTIC ANALGESICS, 2019-2027 ($MILLION)
FIGURE 20.GULF PAIN MANAGEMENT DRUGS MARKET, FOR ARTHRITIC PAIN BY, 2019-2027 ($MILLION)
FIGURE 21.GULF PAIN MANAGEMENT DRUGS MARKET, FOR NEUROPATHIC PAIN, 2019-2027 ($MILLION)
FIGURE 22.GULF PAIN MANAGEMENT DRUGS MARKET, FOR CANCER PAIN, 2019-2027 ($MILLION)
FIGURE 23.GULF PAIN MANAGEMENT DRUGS MARKET, FOR CHRONIC BACK PAIN, 2019-2027 ($MILLION)
FIGURE 24.GULF PAIN MANAGEMENT DRUGS MARKET, FOR POST-OPERATIVE PAIN, 2019-2027 ($MILLION)
FIGURE 25.GULF PAIN MANAGEMENT DRUGS MARKET, FOR MIGRAINE, 2019-2027 ($MILLION)
FIGURE 26.GULF PAIN MANAGEMENT DRUGS MARKET, FOR FIBROMYALGIA, 2019-2027 ($MILLION)
FIGURE 27.GULF PAIN MANAGEMENT DRUGS MARKET, FOR BONE FRACTURE, 2019-2027 ($MILLION)
FIGURE 28.GULF PAIN MANAGEMENT DRUGS MARKET, FOR MUSCLE STRAIN/SPRAIN, 2019-2027 ($MILLION)
FIGURE 29.GULF PAIN MANAGEMENT DRUGS MARKET, FOR ACUTE APPENDICITIS, 2019-2027 ($MILLION)
FIGURE 30.GULF PAIN MANAGEMENT DRUGS MARKET, FOR OTHERS, 2019-2027 ($MILLION)
FIGURE 31.GULF PAIN MANAGEMENT DRUGS MARKET, FOR CHRONIC PAIN, 2019-2027 ($MILLION)
FIGURE 32.GULF PAIN MANAGEMENT DRUGS MARKET, FOR ACUTE PAIN, 2019-2027 ($MILLION)
FIGURE 33.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 34.ABBOTT: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 35.ABBOTT: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 36.ELI LILLY: NET SALES, 2017–2019 ($MILLION)
FIGURE 37.ELI LILLY: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 38.GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 39.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 40.GSK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 41.J&J: NET SALES, 2017–2019 ($MILLION)
FIGURE 42.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 43.J&J: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 44.MERCK & CO., INC.: NET SALES, 2017–2019 ($MILLION)
FIGURE 45.MERCK & CO., INC.: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 46.MERCK & CO., INC.: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 47.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 48.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 49.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 50.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 51.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 52.PFIZER: NET SALES, 2017–2019 ($MILLION)
FIGURE 53.PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 54.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 55.JULPHAR: NET SALES, 2015–2017 ($MILLION)
